Durvalumab: the new standard of care for NSCLC?
PARP inhibitors: game-changers for ovarian cancer patients?
Mansoor Raza Mirza
Phase 2 trial of chemotherapy plus gefitinib as first-line treatment for lung adenocarcinoma
Angiogenesis inhibition in lung cancer
Phase 1b trial of CRS-207 with chemotherapy for malignant pleural mesothelioma